IoM seeks to augment Enzi/Kennedy bill
The Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System seeks to work with Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) on their "Enhancing Drug Safety & Innovation Act." "We certainly hope that when they start negotiations over that bill that the chair of our committee can go and testify in Congress and the bill can incorporate more of what is in the committee report," IoM Committee Study Director Kathleen Stratton said at the Academy of Managed Care Pharmacy Educational Conference Oct. 6. The committee's report, released in September, calls for sweeping changes at FDA (1The Pink Sheet" Oct. 2, 2006, p. 5)...
You may also be interested in...
FDA Drug Safety Reforms Not Enough To Fix Problems, IoM Committee Says
A separate postmarketing safety center may become necessary if the recommendations made by the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System do not result in sufficient reforms of FDA's safety oversight, the committee says
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.
Broad Heart Failure Label Ushers Lexicon’s Inpefa Into SGLT2 Inhibitor Market
Sotagliflozin’s cardiovascular outcomes trials support the most expansive heart failure risk reduction claim approved by the US FDA in the class, a turnaround from the drug’s setbacks in type 1 diabetes.